A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
require prompt reports of marketing status by holders 
of approved applications for biological products, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Biologics Market 
4
Transparency Act of 2022’’. 
5
21:38 Mar 13, 2022
H7035
2 
•HR 7035 IH
SEC. 2. PROMPT REPORTS OF MARKETING STATUS BY 
1
HOLDERS OF APPROVED APPLICATIONS FOR 
2
BIOLOGICAL PRODUCTS. 
3
(a) IN GENERAL.—Section 506I of the Federal Food, 
4
Drug, and Cosmetic Act (21 U.S.C. 356i) is amended— 
5
(1) in subsection (a)— 
6
(A) by striking ‘‘The holder of an applica-
7
tion approved under subsection (c) or (j) of sec-
8
tion 505’’ and inserting ‘‘The holder of an ap-
9
plication approved under subsection (c) or (j) of 
10
section 505 of this Act or subsection (a) or (k) 
11
of section 351 of the Public Health Service 
12
Act’’; and 
13
(B) in paragraph (3), by striking ‘‘or ab-
14
breviated application number’’ and inserting ‘‘, 
15
abbreviated application number, or biologics li-
16
cense application number’’; and 
17
(2) in subsection (b)— 
18
(A) by striking ‘‘The holder of an applica-
19
tion approved under subsection (c) or (j)’’ and 
20
inserting ‘‘The holder of an application ap-
21
proved under subsection (c) or (j) of section 
22
505 of this Act or subsection (a) or (k) of sec-
23
tion 351 of the Public Health Service Act’’; and 
24
(B) in paragraph (2), by striking ‘‘or ab-
25
breviated application number’’ and inserting ‘‘, 
26
21:38 Mar 13, 2022
H7035
3 
•HR 7035 IH
abbreviated application number, or biologics li-
1
cense application number’’. 
2
(b) ADDITIONAL ONE-TIME REPORT.—Subsection 
3
(c) of section 506I of the Federal Food, Drug, and Cos-
4
metic Act (21 U.S.C. 356i) is amended to read as follows: 
5
‘‘(c) ADDITIONAL ONE-TIME REPORT.—Within 180 
6
days of the date of enactment of the Biologics Market 
7
Transparency Act of 2022, all holders of applications ap-
8
proved under subsection (a) or (k) of section 351 of the 
9
Public Health Service Act shall review the information in 
10
the list published under section 351(k)(9)(A) and shall 
11
submit a written notice to the Secretary— 
12
‘‘(1) stating that all of the application holder’s 
13
biological products in the list published under sec-
14
tion 351(k)(9)(a) that are not listed as discontinued 
15
are available for sale; or 
16
‘‘(2) including the information required pursu-
17
ant to subsection (a) or (b), as applicable, for each 
18
of the application holder’s biological products that 
19
are in the list published under section 351(k)(9)(a) 
20
and not listed as discontinued, but have been with-
21
drawn from sale or never have been available for 
22
sale.’’. 
23
21:38 Mar 13, 2022
H7035
4 
•HR 7035 IH
(c) PURPLE BOOK.—Subsections (d) and (e) of sec-
1
tion 506I of the Federal Food, Drug, and Cosmetic Act 
2
(21 U.S.C. 356i) are each amended— 
3
(1) by striking ‘‘the list published under sub-
4
section 505(j)(7)(A)’’ and inserting ‘‘the list pub-
5
lished under section 505(j)(7)(A) of this Act or sec-
6
tion 351(k)(9)(A) of the Public Health Service Act, 
7
as applicable,’’; and 
8
(2) by striking ‘‘in accordance with subsection 
9
505(j)(7)(C)’’ and inserting ‘‘in accordance with sec-
10
tion 505(j)(7)(C) of this Act or section 351(k)(9)(B) 
11
of the Public Health Service Act (as applicable)’’. 
12
Æ 
21:38 Mar 13, 2022
H7035
